This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OvaScience Appoints Hugh Taylor, M.D., To Scientific Advisory Board

OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for female infertility, announced today the appointment of Hugh Taylor, M.D., the Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology at the Yale School of Medicine and Chief of Obstetrics and Gynecology, Yale-New Haven Hospital, to its Scientific Advisory Board. OvaScience also established a research collaboration with Dr. Taylor to develop potential new treatments and diagnostic markers for endometriosis, a leading cause of female infertility. 1

“Dr. Taylor is a world expert and pioneer in the field of endometriosis, a disease that is frequently misdiagnosed and lacking in new treatment options for patients,” said Arthur Tzianabos, Ph.D., Chief Scientific Officer of OvaScience. “We look forward to working with Dr. Taylor to develop new methods for treating and diagnosing this leading cause of female infertility.”

Dr. Taylor has more than 25 years of experience as a clinician and researcher in reproductive medicine. His research focuses on stem cells, uterine development and endometriosis, work that has led to the publication of more than 125 articles. He is currently Editor-in-Chief of Reproductive Sciences. In 2013, Dr. Taylor was recognized by the IVI Foundation for producing the best research in reproductive medicine and in 2012, he was named Honoree of the Year by the Endometriosis Foundation. Dr. Taylor received his undergraduate training at Yale University and received his medical degree from the University of Connecticut School of Medicine. He completed his residency in Obstetrics and Gynecology at Yale. His postdoctoral training included a fellowship in Reproductive Endocrinology and Infertility as well as a fellowship in Molecular Biology, both at Yale.

“This work will help us continue to explore how endometrial stem cells and certain biomarkers of disease can be used to develop new treatments and potentially non-invasive diagnostics for endometriosis,” said Hugh Taylor, M.D., Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology at the Yale School of Medicine and Chief of Obstetrics and Gynecology, Yale-New Haven Hospital. “Our research and OvaScience’s advances in its egg precursor cell technology platform offer exciting possibilities for helping patients who are experiencing the painful effects of endometriosis and infertility.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs